Prices are updated after-hours

ocular

Ocular Therapeutix, Inc.

OCUL | News | $5.0 -1.48% -1.5% 2.3M

(0.0% 1d) (-46.0% 1m) (-18.1% 1y) (0.0% 2d) (0.0% 3d) (-36.2% 7d) (-58.95% volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 773,520,430
http://www.ocutx.com
Sec Filling | Patents | 161 employees

(US) Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

eye ocular

Drugs

DEXTENZA (dexamethasone)

add to watch list Paper trade email alert is off

Eyegate Pharmaceuticals, Inc.

EYEG | $34.735 -0.89% 90

Health Technology

(0.0% 1d) (-2.3% 1m) (-2.4% 1y) (0.0% 2d) (0.0% 3d) (0.2% 7d) (-31.03% volume)
Earnings Calendar:
Market Cap: $ 24,314,500
http://www.eyegatepharma.com
Sec Filling | Patents | 10 employees

(United States) EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.

ocular eye

add to watch list Paper trade email alert is off

Alcon Inc.

ALC | $80.76 0.19% 0.0% 940K

Health Technology

(0.0% 1d) (-2.8% 1m) (10.0% 1y) (0.0% 2d) (0.0% 3d) (1.3% 7d) (-41.52% volume)
Earnings Calendar:
Market Cap: $ 40,355,772,000
http://www.alcon.com
Sec Filling | Patents | 22142 employees

(CH) Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Fribourg, Switzerland.

eye diseases eye ocular

Drugs

FLUORESCITE (fluorescein sodium)

add to watch list Paper trade email alert is off

Oyster Point Pharma, Inc.

OYST | $11.17 0.18% -0.27%

Health Technology

(0.0% 1d) (0.0% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (583.77% volume)
Earnings Calendar: 2023-02-23
Market Cap: $ 299,850,742
http://www.oysterpointrx.com
Sec Filling | Patents | 17 employees

Oyster Point Pharma, Inc. engages in the development and commercialization of pharmaceutical therapies to treat ocular surface diseases. Its product candidate, OC-01, is a nicotinic acetylcholine receptor agonist, which is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. The company was founded by Michael and is Ackermann in June 30, 2015 headquartered in Princeton, NJ.

eye diseases eye ocular msa 3d

add to watch list Paper trade email alert is off

Guardion Health Sciences, Inc.

GHSI | $8.0 -0.75% 1.8K

Health Services

(0.0% 1d) (-11.2% 1m) (34.2% 1y) (0.0% 2d) (0.0% 3d) (-0.9% 7d) (-50.99% volume)
Earnings Calendar: 2022-11-09
Market Cap: $ 10,273,248
http://www.guardionhealth.com
Sec Filling | Patents | 22 employees

(US) Guardion Health Sciences, Inc. engages in the provision of health care services. It offers medical food involving the ocular health space. The firm also develops medical devices that measures macular pigment density. The company was founded by Michael Favish in 2009 and is headquartered in San Diego, CA.

ocular nutrition eye food macular

add to watch list Paper trade email alert is off

eMagin Corporation

EMAN | $2.07 0.0% 3.6M

Electronic Technology

(0.0% 1d) (0.0% 1m) (8.9% 1y) (0.0% 2d) (0.0% 3d) (3.0% 7d) (678.1% volume)
Earnings Calendar:
Market Cap: $ 172,198,986
http://www.eMagin.com
Sec Filling | Patents | 96 employees

(US) eMagin Corp. engages in the design, development, manufacture, and marketing of organic light emitting diode (OLED) miniature displays and related products. Its OLED displays are incorporated with products including military aviation helmets, military weapons sights and targeting systems, night vision and thermal imaging devices, training and simulation, visualization for ocular surgery, mobile ultrasound, and augmented reality applications. The company was founded on January 23, 1996 and is headquartered in Hopewell Junction, NY.

ocular augmented reality military

add to watch list Paper trade email alert is off

Tarsus Pharmaceuticals, Inc.

TARS | $33.73 4.46% 4.27% 220K

Health Technology

(0.0% 1d) (-5.3% 1m) (120.9% 1y) (0.0% 2d) (0.0% 3d) (-6.2% 7d) (NaN% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 1,154,203,025
http://www.tarsusrx.com
Sec Filling | Patents | 20 employees

Tarsus Pharmaceuticals, Inc. develops and manufactures drug treatments for Blepharitis. The company focuses on treatment of Blepharitis, which is a common ocular condition, characterized by inflammation of the eyelid, which can impact the anterior or posterior lid or both. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

ocular eye lidar treatment

add to watch list Paper trade email alert is off

Modular Medical, Inc.

MODD 4 | $1.6 -0.62% 75K

(0.0% 1d) (-19.2% 1m) (-16.4% 1y) (0.0% 2d) (0.0% 3d) (-5.9% 7d) (11.08% volume)
Earnings Calendar:
Market Cap: $ 35,038,493

Sec Filling | Patents | 20 employees

modular medical ltd is a company based out of beacon house orchard farm ivinghoe aston, buckinghamshire, united kingdom.

add to watch list Paper trade email alert is off

Aadi Biosciences Inc

AADI | $1.845 -2.9% -2.98% 84K

Manufacturing

(0.0% 1d) (-12.4% 1m) (-76.0% 1y) (0.0% 2d) (0.0% 3d) (3.3% 7d) (27.03% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 45,302,508
https://www.aerpio.com
Sec Filling | Patents | 12 employees

(US) Aerpio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing compounds that activate Tie2 for indications in which the Company believes that activation of Tie2 may have therapeutic potential. The Company's lead compound, razuprotafib (formerly AKB-9778), a first-in-class small molecule inhibitor of vascular endothelial protein tyrosine phosphatase ("VE-PTP"). The Company is also evaluating development options for ARP-1536, a humanized monoclonal antibody, for its therapeutic potential in the treatment of diabetic vascular complications including nephropathy and diabetic macular edema ("DME"). The Company's third asset is a bispecific antibody that binds both VEGF and VE-PTP which is designed to inhibit VEGF activation and activate Tie2. This bispecific antibody has the potential to be an improved treatment for wet age-related macular degeneration and DME via intravitreal injection. Finally, the Company has exclusively out-licensed AKB-4924 (now called GB004), a first-in-class small molecule inhibitor of hypoxia-inducible factor-1 (HIF). GB004 is being developed by AKB-4924's exclusive licensor, Gossamer Bio, Inc.. In January 2021, the Company announced that it had initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from the Company's clinical assets and cash resources.

monoclonal antibodies antibody treatment diabetic diabetes injection macular

add to watch list Paper trade email alert is off

Opthea Limited

OPT | News | $3.38 2.37% 2K

Health Technology

(0.0% 1d) (-8.6% 1m) (-3.0% 1y) (0.0% 2d) (0.0% 3d) (-0.6% 7d) (134.17% volume)
Earnings Calendar:
Market Cap: $ 280,036,647
http://www.opthea.com
Sec Filling | Patents | 18 employees

(AU) Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It targets to treat neovascular age-related macular degeneration (wet AMD) and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984 and is headquartered in South Yarra, Australia.

diabetes diabetic macular dmd treatment

add to watch list Paper trade email alert is off

Alimera Sciences, Inc.

ALIM | $3.59 1.41% 1.39% 16K

Health Technology

(0.0% 1d) (-11.3% 1m) (71.1% 1y) (0.0% 2d) (0.0% 3d) (6.0% 7d) (-45.97% volume)
Earnings Calendar: 2023-10-26
Market Cap: $ 187,952,476
http://www.alimerasciences.com
Sec Filling | Patents | 127 employees

(US) Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.

diabetes diabetic macular treatment

Drugs

Iluvien (fluocinolone acetonide)

add to watch list Paper trade email alert is off

KalVista Pharmaceuticals, Inc.

KALV | News | $11.21 -2.01% -2.05% 190K

Health Technology

(0.0% 1d) (2.8% 1m) (42.6% 1y) (0.0% 2d) (0.0% 3d) (-1.8% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 472,930,798
http://www.kalvista.com
Sec Filling | Patents | 56 employees

(US) KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME). The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello and is headquartered in Cambridge, MA.

diabetes diabetic macular hereditary angioedema

add to watch list Paper trade email alert is off

Rezolute Inc.

RZLT 4 | $2.86 -19.21% -23.78% 930K

Technology Services

(0.0% 1d) (87.3% 1m) (67.0% 1y) (0.0% 2d) (0.0% 3d) (9.3% 7d) (NaN% volume)
Earnings Calendar: 2024-02-09
Market Cap: $ 114,765,070
http://www.rezolutebio.com
Sec Filling | Patents | 23 employees

(US) Rezolute, Inc. is biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

insulin antibody diabetes diabetic macular metabolic injection

add to watch list Paper trade email alert is off

Adverum Biotechnologies, Inc.

ADVM | News | $10.96 -3.35% -3.47% 310K

Health Technology

(0.0% 1d) (-24.1% 1m) (1157.2% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (21.12% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 2,274,738,706
http://www.adverum.com
Sec Filling | Patents | 114 employees

(US) Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.

gene therapies macular treatment hereditary angioedema

add to watch list Paper trade email alert is off